Metraipolis › archive › dc_3989f79dbe0d

Cost-effectiveness analysis of pyrotinib combined with trastuzumab and docetaxel as first-line treatment for HER2-positive metastatic breast cancer in China — Europe PMC PMID:42428506

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42428506
DOI
10.3389/fphar.2026.1845724
License (as archived)
solo-consultazione
Archived
2026-10-19T01:55:10.335Z
SHA-256 of the archived text
00f0ce1d26ac26d4fbba02387ed75ebd933d5f678743cd4d22d1b49381afcba8
Stable URL of this page
https://metraipolis.com/documento/dc_3989f79dbe0d

How to cite

Cost-effectiveness analysis of pyrotinib combined with trastuzumab and docetaxel as first-line treatment for HER2-positive metastatic breast cancer in China — Europe PMC PMID:42428506 — Europe PMC (en), https://europepmc.org/article/MED/42428506 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_3989f79dbe0d (Metraipolis archive dc_3989f79dbe0d, sha256 00f0ce1d26ac26d4fbba02387ed75ebd933d5f678743cd4d22d1b49381afcba8)
BibTeX
@misc{dc3989f79dbe0d,
  title = {Cost-effectiveness analysis of pyrotinib combined with trastuzumab and docetaxel as first-line treatment for HER2-positive metastatic breast cancer in China — Europe PMC PMID:42428506},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42428506},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_3989f79dbe0d; sha256 00f0ce1d26ac26d4fbba02387ed75ebd933d5f678743cd4d22d1b49381afcba8},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42428506. Agents can read the archived copy with the MCP tool read_document.